Format

Send to

Choose Destination
Appl Health Econ Health Policy. 2019 Oct;17(5):733-740. doi: 10.1007/s40258-019-00492-5.

Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA.

Author information

1
Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Mail Stop M3-B232, Seattle, WA, 98109, USA. lsteuten@ohe.org.
2
The Office of Health Economics, 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT, UK. lsteuten@ohe.org.
3
EMD Serono, 1 Technology Place, Rockland, MA, 02370, USA.
4
Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA.
5
School of Pharmacy, University of Washington, 1959 Northeast Pacific Street, Campus Box: 357630, Seattle, WA, 98195, USA.
6
Division of Dermatology, Department of Medicine, University of Washington, 850 Republican Street, Box 358050, Seattle, WA, 98109, USA.
7
Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Mail Stop M3-B232, Seattle, WA, 98109, USA.

Abstract

BACKGROUND:

Merkel cell carcinoma (MCC) is a rare and aggressive type of cancer with poor outcomes.

OBJECTIVE:

To describe treatment patterns, overall survival, and healthcare costs associated with advanced MCC (aMCC) using data from Medicare enrollees who received an aMCC diagnosis in the USA States between 2006 and 2013.

METHODS:

Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 2006 to 2013 were used to describe treatment patterns, 1- and 5-year overall survival, and total healthcare costs for the periods 12 months before aMCC diagnosis and 4-12 months afterward in patients aged ≥ 65 years.

RESULTS:

We identified 257 patients with an aMCC diagnosis, of whom 51% had stage IIIb disease and 49% had stage IV. Within 4 months after diagnosis, 84% of patients (n = 216) received treatment; 45% (n = 115) received surgery, 48% (n = 124) radiation therapy, and 31% (n = 80) chemotherapy. Second-line chemotherapy was administered in 33% of patients (n = 26) receiving first-line chemotherapy. Median overall survival was 27 months in patients whose aMCC was diagnosed at stage IIIb and 12 months in patients whose aMCC was diagnosed at stage IV. Median total 12-month direct healthcare costs were US$48,006 (25th-75th percentile range = US$30,594-US$69,797) per patient. Total costs were highest in patients receiving chemotherapy, either alone or combined with radiation and/or surgery (US$52,854; 25th-75th percentile range = US$34,473-US$71,987).

CONCLUSION:

Most patients with aMCC received initial treatment, including surgery, radiation, and/or chemotherapy, and approximately one-third of those receiving chemotherapy received second-line chemotherapy. Total 12-month direct healthcare costs were highest in patients who received chemotherapy alone or combined with radiation and/or surgery. These poor survival results and high treatment costs highlight the need for effective new aMCC therapies.

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center